The mechanistic advantages of Opamtistomig have been validated in multiple tumor types, including extrapulmonary neuroendocrine carcinoma (EP-NEC), non-small cell lung cancer (NSCLC), small cell lung ...

The PD-1 and PD-L1 inhibitors competitive landscape report delivers important insights into approved as well as ongoing research of 200+ pipeline PD-1 and PD-L1 inhibitor drugs, clinical strategies, ...

Filing supports potential development of radiopharmaceuticals, T-cell engagers and other immune-based approaches using a versatile platform approach SEATTLE, WA / ACCESS Newswire / July 27, 2026 / ...

Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that the Center for Drug Evaluation (CDE) ...

The potential of Opamtistomig as an IO 2.0 pan-tumor cornerstone therapy has been continuously validated across three dimensions: broad-spectrum anti-tumor activity, long-term survival benefit trends, ...

Durvalumab targets PD-L1, a key immune checkpoint. Normally, antigen-presenting cells (APCs) recognize cancer cell antigens and activate cytotoxic T cells, which travel to the tumor site for ...

Cancer immunotherapies are saving lives, but there are big differences in patient responses. Improved understanding of the biology of immune checkpoints might offer some clues. Cancer treatment has ...

A new review article outlines the latest research and results into programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1) inhibitors for the treatment of myelodysplastic syndromes (MDS) ...

The Practical Application of Emerging Technologies Influencing the Diagnosis and Care of Patients With Primary Brain Tumors Comprehensive next-generation sequencing platforms provide tumor genomic ...

Personalized recommendations for patients with non–small cell lung cancer with squamous histology could benefit from research on treatment choice and biomarkers, noted Blythe Adamson, PhD, MPH, ...